Novo Nordisk Sues Sanofi-Aventis Over Insulin Delivery Patents

Law360, New York (September 6, 2005, 12:00 AM EDT) -- Danish drug maker Novo Nordisk A/S has sued its French rival Sanofi-Aventis over patents for its device for administering insulin to people living with diabetes.

Sanofi-Aventis’ handheld OptiClik is an insulin delivery device, or “insulin pen” for Type 1 and Type 2 diabetes. Novo Nordisk alleges the device infringes on of its patents, prompting the complaint filed in U.S. District Court for Delaware.

The complaint accuses Sanofi-Aventis of willful and deliberate infringement, while seeking attorney’s fees, as well as preliminary and permanent injunctions. Also named in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.